iOmx Therapeutics

iOmx Therapeutics is a company founded in 2016 headquartered in Germany. Its most recent tracked round is Series B. Brouky classifies it under Healthcare & Life Sciences. Brouky records 3 investors associated with the company.

iOmx Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class cancer immunotherapies targeting novel immune checkpoints hijacked by cancer cells. The company utilizes its proprietary iOTarg high-throughput screening platform to identify and advance promising drug candidates aimed at treating cancers resistant to current immunotherapies.